Rafael Holdings, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended January 31, 2024 (fiscal Q2 2024). Financial statements are unaudited. Unless noted, amounts are in U.S. dollars.
Business context
Rafael is a holding company with investments and operating interests in early-stage and clinical-stage healthcare businesses, including LipoMedix, Cyclo Therapeutics, Day Three Labs and Rafael Medical Devices, as well as a small remaining real estate interest in Israel. Its healthcare segment generated no revenue. The company says it curtailed early-stage research spending in November 2022 while pursuing strategic investment opportunities.
Financial performance and position
- Revenue: $68,000 for the quarter and $136,000 for the six months, almost entirely rental income. Revenue was $70,000 and $140,000, respectively, in the prior-year periods. Related parties accounted for 40% of revenue in both 2024 periods.
- Operating results: Operating loss was $3.14 million for the quarter and $5.62 million for six months, compared with losses of $4.26 million and $9.40 million a year earlier. Lower R&D spending contributed to the improvement.
- Net income: Net income attributable to Rafael was $6.05 million for the quarter and $2.41 million for six months, versus losses of $3.25 million and $1.66 million in the prior-year periods. Results included noncash unrealized Cyclo investment gains of $9.72 million for the quarter and $7.59 million for six months, partly offset by a $1.63 million loss on remeasurement of the previously held Day Three interest. Six-month 2023 results included a $6.78 million gain on sale of the 520 Property.
- Per-share results: Basic and diluted EPS were $0.26 and $0.25 for the quarter; six-month basic and diluted EPS were each $0.10.
- Cash flow: Continuing operating activities used $4.66 million in the six months, versus $7.44 million in the prior-year period. Investing activities used $9.58 million, including $6.79 million invested in Cyclo; financing activities used $125,000. Cash and cash equivalents declined $14.36 million to $7.14 million.
- Liquidity and debt: Available-for-sale securities were $64.59 million, bringing cash and those securities to approximately $71.72 million. Working capital was $71.81 million. Total liabilities were $3.90 million, including a $1.70 million installment note payable due in November 2024. Management expects cash and available-for-sale securities to cover obligations for at least 12 months from the filing date.
- Assets and equity: Total assets were $106.15 million, compared with $98.83 million at July 31, 2023. Rafael-attributable equity was $102.25 million. Cyclo was carried at $19.57 million, versus $4.76 million at July 31, 2023; Rafael held about 40% of Cyclo’s common shares at January 31.
Material changes and developments
- Day Three: Rafael obtained control on January 2, 2024, acquiring 79% of its outstanding common shares and consolidating it. Preliminary acquisition accounting included $3.57 million of goodwill, $1.89 million of net intangible assets, and a $1.70 million remaining installment-note liability. The purchase-price allocation remains preliminary.
- Cyclo: The increase in reported value materially boosted earnings, but the fair-value gain was noncash. The position includes publicly quoted shares and warrants valued using Level 3 assumptions; the warrants were valued at $2.50 million at January 31.
- Share repurchases: Rafael repurchased 101,487 Class B shares for $168,000 during the six months. The program was suspended on December 22, 2023.
- Available-for-sale securities: The $64.59 million portfolio consisted mainly of corporate bonds; all reported maturities were within one year. No credit-loss allowance was recorded.
Outlook, risks and unusual items
- Subsequent Cornerstone restructuring: On March 13, 2024, after the reporting date, Rafael converted approximately $29.2 million of Cornerstone line-of-credit debt and $2.1 million of promissory-note debt into Cornerstone common shares, converted preferred shares, and invested a further $1.5 million in cash. Rafael reported control of approximately 67% of Cornerstone’s voting equity and expects to consolidate it. The initial accounting was incomplete when the 10-Q was filed, so acquisition-date asset, liability, noncontrolling-interest and pro forma details were not yet available.
- The restructuring follows earlier failures of Cornerstone’s Phase 3 devimistat trials; the filing previously described the associated Cornerstone loans, receivables and investment as fully impaired. The new restructuring could materially affect future reported results and asset valuations.
- No numerical earnings or revenue guidance was provided. Management’s stated liquidity outlook is that cash and available-for-sale securities should fund obligations for at least 12 months from filing.
- Key risks include volatility in Cyclo’s share price and warrant valuation, clinical-stage investment uncertainty, limited operating revenue, and reliance on related parties. One related party represented 45% of accounts receivable at January 31. The filing reports no material change in previously disclosed risk factors and no legal proceedings expected to materially affect results, cash flow or financial condition.
- Management concluded disclosure controls were effective as of January 31, 2024; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- How the Cornerstone restructuring and new consolidation will be accounted for, including the value and recoverability of converted debt and resulting goodwill or other assets.
- How much of reported earnings depends on noncash Cyclo fair-value gains, and how sensitive the warrant valuation is to market and model assumptions.
- Whether available liquidity remains adequate against ongoing cash use, the November 2024 installment payment, and additional investment needs.
- The financial and governance implications of related-party transactions, revenue concentration and Rafael’s control relationships.
- Progress and funding needs across the clinical-stage portfolio, including the impact of prior devimistat trial outcomes.